Abstract

Aim: Botulinum toxin type A (BTX-A) treatment for facial rejuvenation has
 been started to used widely and become the most common aesthetic procedure. The aim in
 this study to evaluate the patients features and outcomes who had Onabotulinumtoxin A.
 Material and Method: The data of the BTX-A patient’s gender, age, occupation, history of cosmetic
 procedures, history of disease, doses of the first and control injections, complications and
 expectations from the therapy collected from the medical records. The patients were divided
 into two groups as under the age of 45 and age of 45 and older. These groups were compared
 with each other in terms of mentioned variables.
 Results: A total of 200 patients included in this study. The mean botulinum toxin dose was
 33.7 units and the mean control dose was 4.5 units. Three (1.5%) of the patients developed a
 complication, all of them were eyelid ptosis. Most common expectation from the toxin
 injection was to look more young (69%) and vigorous (75.5%). There were no significant
 difference between the under the age of 45 and 45 and older group in terms of total BTX-A
 dose and control dose and complication rate (p=0.8, p=0.5, p=0.6). Expectation of looking
 less angry and less saggy were significantly higher in the 45 year and older group (p=0.02,
 p=0.02).
 Conclusion: It is important to evaluate the patient’s gender, age and expectations from the
 botulinum toxin injection to get the highest efficiency from BTX-A injection.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call